These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 11310375)

  • 21. The role of bcl-2, p53, and ki-67 index in predicting tumor recurrence for low grade superficial transitional cell bladder carcinoma.
    Wu TT; Chen JH; Lee YH; Huang JK
    J Urol; 2000 Mar; 163(3):758-60. PubMed ID: 10687971
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Novel p53/p130 axis in bladder tumors.
    Mudryj M; Reay E; Beckett L; Dandekar S; deVere White R; Gandour-Edwards R
    Urology; 2007 Sep; 70(3):608-12. PubMed ID: 17905135
    [TBL] [Abstract][Full Text] [Related]  

  • 23. bcl-2/bax expression and p53 gene status in human bladder cancer: relationship to early recurrence with intravesical chemotherapy after resection.
    Ye D; Li H; Qian S; Sun Y; Zheng J; Ma Y
    J Urol; 1998 Dec; 160(6 Pt 1):2025-8; discussion 2029. PubMed ID: 9817315
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Comparative study of the expression of p53, Ki-67, bcl-2 and CK20 in superficial transitional carcinoma of the bladder: correlation with recurrence, histological grade, and clinical stage].
    San Miguel Fraile P; Antón Badiola I; Ortiz Rey JA; Alvarez Alvarez C; Fernández Costas A; Lago Fernández M; Pelaez Boismorand E; Zungri Telo E; De La Fuente Buceta A
    Actas Urol Esp; 2003 Sep; 27(8):587-93. PubMed ID: 14587233
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Androgen receptor expression is inversely correlated with pathologic tumor stage in bladder cancer.
    Boorjian S; Ugras S; Mongan NP; Gudas LJ; You X; Tickoo SK; Scherr DS
    Urology; 2004 Aug; 64(2):383-8. PubMed ID: 15302512
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The prevalence of bcl-2, p53, and Ki-67 immunoreactivity in transitional cell bladder carcinomas and their clinicopathologic correlates.
    Nakopoulou L; Vourlakou C; Zervas A; Tzonou A; Gakiopoulou H; Dimopoulos MA
    Hum Pathol; 1998 Feb; 29(2):146-54. PubMed ID: 9490274
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Expression of mutant P53 gene protein product in human bladder carcinoma].
    Ye DW
    Zhonghua Wai Ke Za Zhi; 1993 Aug; 31(8):484-6. PubMed ID: 8112175
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic implications of p53 gene mutations in bladder tumors.
    Lorenzo-Romero JG; Salinas-Sánchez AS; Giménez-Bachs JM; Sánchez-Sánchez F; Escribano-Martínez J; Segura-Martín M; Hernandez-Millán IR; Virseda-Rodríguez JA
    J Urol; 2003 Feb; 169(2):492-9. PubMed ID: 12544295
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Implications of p53 gene mutations on patient survival in transitional cell carcinoma of the bladder: a long-term study.
    Salinas-Sánchez AS; Lorenzo-Romero JG; Giménez-Bachs JM; Sánchez-Sánchez F; Donate-Moreno MJ; Rubio-Del-Campo A; Hernández-Millán IR; Segura-Martín M; Atienzar-Tobarra M; Escribano-Martínez J
    Urol Oncol; 2008; 26(6):620-6. PubMed ID: 18367096
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Assessment of the transcriptional activity of p53 improves the prediction of recurrence in superficial transitional cell carcinoma of the bladder.
    Dekairelle AF; Tombal B; Cosyns JP; Gala JL
    Clin Cancer Res; 2005 Jul; 11(13):4724-32. PubMed ID: 16000567
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Stage, grade and behavior of bladder urothelial carcinoma defined by the microRNA expression profile.
    Dip N; Reis ST; Timoszczuk LS; Viana NI; Piantino CB; Morais DR; Moura CM; Abe DK; Silva IA; Srougi M; Dall'Oglio MF; Leite KR
    J Urol; 2012 Nov; 188(5):1951-6. PubMed ID: 22999546
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Invasion of the bladder by transitional cell carcinoma: its relation to histologic grade and expression of p53, MIB-1, c-erb B-2, epidermal growth factor receptor, and bcl-2.
    Vollmer RT; Humphrey PA; Swanson PE; Wick MR; Hudson ML
    Cancer; 1998 Feb; 82(4):715-23. PubMed ID: 9477105
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cyclooxygenase-2 is highly expressed in carcinoma in situ and T1 transitional cell carcinoma of the bladder.
    Shariat SF; Kim JH; Ayala GE; Kho K; Wheeler TM; Lerner SP
    J Urol; 2003 Mar; 169(3):938-42. PubMed ID: 12576817
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Urinary and tissue levels of scatter factor in transitional cell carcinoma of bladder.
    Rosen EM; Joseph A; Jin L; Yao Y; Chau MH; Fuchs A; Gomella L; Hastings H; Goldberg ID; Weiss GH
    J Urol; 1997 Jan; 157(1):72-8. PubMed ID: 8976219
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic impact of p63 and p53 expression in upper urinary tract transitional cell carcinoma.
    Zigeuner R; Tsybrovskyy O; Ratschek M; Rehak P; Lipsky K; Langner C
    Urology; 2004 Jun; 63(6):1079-83. PubMed ID: 15183954
    [TBL] [Abstract][Full Text] [Related]  

  • 36. p53 Gene mutations in superficial bladder cancer.
    Lorenzo Romero JG; Salinas Sánchez AS; Giménez Bachs JM; Sánchez Sánchez F; Escribano Martínez J; Hernández Millán IR; Segura Martín M; Virseda Rodríguez JA
    Urol Int; 2004; 73(3):212-8. PubMed ID: 15539839
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An immunohistochemical and prognostic evaluation of cathepsin D expression in 105 bladder carcinomas.
    Dickinson AJ; Fox SB; Newcomb PV; Persad RA; Sibley GN; Harris AL
    J Urol; 1995 Jul; 154(1):237-41. PubMed ID: 7776437
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The prevalence and clinicopathologic correlate of p16INK4a, retinoblastoma and p53 immunoreactivity in locally advanced urinary bladder cancer.
    Tzai TS; Tsai YS; Chow NH
    Urol Oncol; 2004; 22(2):112-8. PubMed ID: 15082007
    [TBL] [Abstract][Full Text] [Related]  

  • 39. p53 mutations and prognosis in bladder tumors.
    Uchida T; Wada C; Ishida H; Wang C; Egawa S; Yokoyama E; Kameya T; Koshiba K
    J Urol; 1995 Apr; 153(4):1097-104. PubMed ID: 7869472
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Frequent association of p53 gene mutation in invasive bladder cancer.
    Fujimoto K; Yamada Y; Okajima E; Kakizoe T; Sasaki H; Sugimura T; Terada M
    Cancer Res; 1992 Mar; 52(6):1393-8. PubMed ID: 1540947
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.